Kadmon waxes rhapsodic on cGVHD results as race with Jakafi heats up
A year ago, Kadmon piqued cautious interest and sent its stock up 20% when it announced positive results from a tiny proof-of-concept study on a new, chronic graft-versus-host-disease treatment. Now interim results are out on the pivotal, and not just the biotech’s executives are gushing about it.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 77,700+ biopharma pros reading Endpoints daily — and it's free.